Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Histone acetyltransferase GCN5 | 0.0044 | 0.169 | 0.5 |
Schistosoma mansoni | zinc finger protein | 0.0026 | 0.0466 | 0.0466 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0134 | 0.7856 | 0.7856 |
Leishmania major | tyrosyl-DNA phosphodiesterase 1 | 0.0074 | 0.3759 | 0.5 |
Schistosoma mansoni | gcn5proteinral control of amino-acid synthesis 5-like 2 gcnl2 | 0.0165 | 1 | 1 |
Trypanosoma brucei | tyrosyl-DNA Phosphodiesterase (Tdp1), putative | 0.0074 | 0.3759 | 0.5 |
Loa Loa (eye worm) | tyrosyl-DNA phosphodiesterase | 0.0074 | 0.3759 | 0.3759 |
Loa Loa (eye worm) | hypothetical protein | 0.005 | 0.2091 | 0.2091 |
Plasmodium vivax | histone acetyltransferase GCN5, putative | 0.005 | 0.2145 | 0.5 |
Echinococcus multilocularis | gcn5proteinral control of amino acid synthesis | 0.0165 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.2238 | 0.2238 |
Echinococcus multilocularis | transcription factor Dp 1 | 0.0043 | 0.1624 | 0.1624 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0023 | 0.0275 | 0.0275 |
Loa Loa (eye worm) | bromodomain containing protein | 0.0024 | 0.032 | 0.032 |
Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.412 | 0.412 |
Echinococcus multilocularis | zinc finger protein | 0.0026 | 0.0466 | 0.0466 |
Trypanosoma cruzi | tyrosyl-DNA Phosphodiesterase (Tdp1), putative | 0.0074 | 0.3759 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0023 | 0.0275 | 0.0275 |
Plasmodium falciparum | histone acetyltransferase GCN5 | 0.0044 | 0.169 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0071 | 0.3547 | 0.3547 |
Brugia malayi | Tyrosyl-DNA phosphodiesterase family protein | 0.0074 | 0.3759 | 0.316 |
Schistosoma mansoni | tyrosyl-DNA phosphodiesterase | 0.0074 | 0.3759 | 0.3759 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.005 | 0.2145 | 0.2256 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0025 | 0.0421 | 0.0443 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.0158 | 0.9506 | 1 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.004 | 0.1449 | 0.1525 |
Entamoeba histolytica | tyrosyl-DNA phosphodiesterase, putative | 0.0074 | 0.3759 | 1 |
Trichomonas vaginalis | bromodomain-containing protein, putative | 0.005 | 0.2145 | 0.5 |
Echinococcus granulosus | zinc finger protein | 0.0026 | 0.0466 | 0.0491 |
Brugia malayi | Bromodomain containing protein | 0.0088 | 0.4721 | 0.4215 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0071 | 0.3547 | 0.3731 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.004 | 0.1449 | 0.1449 |
Trichomonas vaginalis | cat eye syndrome critical region protein 2, cscr2, putative | 0.005 | 0.2145 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0134 | 0.7856 | 0.7856 |
Loa Loa (eye worm) | acetyltransferase | 0.0165 | 1 | 1 |
Schistosoma mansoni | bromodomain containing protein | 0.0075 | 0.3822 | 0.3822 |
Brugia malayi | Bromodomain containing protein | 0.0047 | 0.1904 | 0.1127 |
Trypanosoma cruzi | tyrosyl-DNA Phosphodiesterase (Tdp1), putative | 0.0074 | 0.3759 | 0.5 |
Echinococcus multilocularis | tyrosyl DNA phosphodiesterase 1 | 0.0074 | 0.3759 | 0.3759 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0025 | 0.0421 | 0.0421 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-A | 0.005 | 0.2145 | 0.5 |
Brugia malayi | MH2 domain containing protein | 0.0134 | 0.7856 | 0.7651 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0025 | 0.0421 | 0.0421 |
Echinococcus granulosus | tyrosyl DNA phosphodiesterase 1 | 0.0074 | 0.3759 | 0.3954 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-B | 0.005 | 0.2145 | 0.5 |
Echinococcus granulosus | transcription factor Dp 1 | 0.0043 | 0.1624 | 0.1709 |
Loa Loa (eye worm) | hypothetical protein | 0.0043 | 0.1637 | 0.1637 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.